Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Integra LifeSciences Holdings Corporation (NASDAQ:IART) Share Price
Media headlines about Integra LifeSciences Holdings Corporation (NASDAQ:IART) have been trending somewhat positive on Saturday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Integra LifeSciences Holdings Corporation earned a news impact score of 0.14 on Accern’s scale. Accern also assigned news stories about the life sciences company an impact score of 46.0623146138114 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Integra’s DuraSeal® dural sealant saves healthcare costs according to a study recently published in the Journal of Health Economics and Outcomes Research (finance.yahoo.com)
- See what the IHS Markit Score report has to say about Integra Lifesciences Holdings Corp. (finance.yahoo.com)
- ETFs with exposure to Integra LifeSciences Holdings Corp. : August 11, 2017 (finance.yahoo.com)
- Integra LifeSciences Holdings Corporation (IART) Receives Average Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- Zacks: Analysts Anticipate Integra LifeSciences Holdings Corporation (NASDAQ:IART) Will Post Quarterly Sales of $286.10 Million (americanbankingnews.com)
Several research analysts recently commented on the stock. UBS AG reaffirmed a “buy” rating and issued a $60.00 price objective (up from $48.00) on shares of Integra LifeSciences Holdings Corporation in a report on Friday, June 9th. Oppenheimer Holdings, Inc. set a $60.00 price objective on shares of Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a report on Saturday, June 24th. Zacks Investment Research raised shares of Integra LifeSciences Holdings Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. Raymond James Financial, Inc. raised their price objective on shares of Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the stock an “outperform” rating in a report on Thursday, July 27th. Finally, Cantor Fitzgerald assumed coverage on shares of Integra LifeSciences Holdings Corporation in a report on Thursday, June 29th. They issued an “overweight” rating and a $65.00 price objective for the company. Five research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $52.63.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) opened at 49.52 on Friday. The company has a market capitalization of $3.87 billion, a P/E ratio of 60.39 and a beta of 0.73. Integra LifeSciences Holdings Corporation has a one year low of $40.51 and a one year high of $88.86. The firm has a 50-day moving average of $52.61 and a 200 day moving average of $46.95.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The firm had revenue of $282.16 million during the quarter, compared to analyst estimates of $283.58 million. During the same quarter in the prior year, the business earned $0.40 earnings per share. Integra LifeSciences Holdings Corporation’s revenue for the quarter was up 13.2% on a year-over-year basis. On average, equities analysts forecast that Integra LifeSciences Holdings Corporation will post $1.90 EPS for the current fiscal year.
In related news, Director Stuart Essig sold 140,000 shares of the company’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $48.01, for a total transaction of $6,721,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Donald E. Morel, Jr. bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The shares were bought at an average price of $49.25 per share, with a total value of $492,500.00. Following the transaction, the director now owns 29,612 shares of the company’s stock, valued at approximately $1,458,391. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 17,550 shares of company stock valued at $864,842. 21.50% of the stock is owned by company insiders.
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.